Sickle Cell Disease News

Investigational SCD therapy shows stronger results at higher dose

A Phase 1b trial shows the higher dose of pociredir boosts fetal hemoglobin levels in adults with sickle cell disease.
Yahoo Finance

FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac ...

DENVER, April 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients ...
Taiwan News

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American ...

― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at Week ...
The State

ASTCT Response to FDA Approval of Gene Therapies for Treatment of Sickle Cell Disease (SCD)

CHICAGO, December 13, 2023 (Newswire.com) - The American Society for Transplantation and Cellular Therapy® (ASTCT®) recognizes the US Food and Drug Administration's (FDA) recently granted approval for ...